Industry Growth Insights published a new data on “Chimeric Antigen Receptor Cell Therapy Market”. The research report is titled “Chimeric Antigen Receptor Cell Therapy Market research by Types (Monotherapy, Combination Therapy), By Applications (Acute Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma, Transplant Rejection, Other), By Players/Companies Amgen Inc, Autolus Therapeutics Plc, Beijing Immunochina Medical Science & Technology Co Ltd, Bellicum Pharmaceuticals Inc, Bristol-Myers Squibb Co, bluebird bio Inc, CARsgen Therapeutics Ltd, Celgene Corp, Cell Medica Ltd, Cellular Biomedicine Group Inc, Celularity Inc, Celyad SA, Daiichi Sankyo Co Ltd, Fosun Pharmaceutical AG, Gilead Sciences Inc, Guangzhou Anjie Biomedical Technology Co Ltd, Hangzhou Converd Co Ltd, Hebei Senlang Biotechnology Inc Ltd, HRAIN Biotechnology Co Ltd, Juno Therapeutics Inc, Kite Pharma Inc, Nanjing Legend Biotech Co Ltd, NantKwest Inc, Nkarta Inc, Novartis AG, Ono Pharmaceutical Co Ltd, Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, Sorrento Therapeutics Inc, Takara Bio Inc”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Chimeric Antigen Receptor Cell Therapy Market Research Report
By Type
Monotherapy, Combination Therapy
By Application
Acute Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma, Transplant Rejection, Other
By Companies
Amgen Inc, Autolus Therapeutics Plc, Beijing Immunochina Medical Science & Technology Co Ltd, Bellicum Pharmaceuticals Inc, Bristol-Myers Squibb Co, bluebird bio Inc, CARsgen Therapeutics Ltd, Celgene Corp, Cell Medica Ltd, Cellular Biomedicine Group Inc, Celularity Inc, Celyad SA, Daiichi Sankyo Co Ltd, Fosun Pharmaceutical AG, Gilead Sciences Inc, Guangzhou Anjie Biomedical Technology Co Ltd, Hangzhou Converd Co Ltd, Hebei Senlang Biotechnology Inc Ltd, HRAIN Biotechnology Co Ltd, Juno Therapeutics Inc, Kite Pharma Inc, Nanjing Legend Biotech Co Ltd, NantKwest Inc, Nkarta Inc, Novartis AG, Ono Pharmaceutical Co Ltd, Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, Sorrento Therapeutics Inc, Takara Bio Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
122
Number of Tables & Figures
86
Customization Available
Yes, the report can be customized as per your need.
Global Chimeric Antigen Receptor Cell Therapy Market Report Segments:
The global Chimeric Antigen Receptor Cell Therapy market is segmented on the basis of:
Types
Monotherapy, Combination Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Acute Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma, Transplant Rejection, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen Inc
- Autolus Therapeutics Plc
- Beijing Immunochina Medical Science & Technology Co Ltd
- Bellicum Pharmaceuticals Inc
- Bristol-Myers Squibb Co
- bluebird bio Inc
- CARsgen Therapeutics Ltd
- Celgene Corp
- Cell Medica Ltd
- Cellular Biomedicine Group Inc
- Celularity Inc
- Celyad SA
- Daiichi Sankyo Co Ltd
- Fosun Pharmaceutical AG
- Gilead Sciences Inc
- Guangzhou Anjie Biomedical Technology Co Ltd
- Hangzhou Converd Co Ltd
- Hebei Senlang Biotechnology Inc Ltd
- HRAIN Biotechnology Co Ltd
- Juno Therapeutics Inc
- Kite Pharma Inc
- Nanjing Legend Biotech Co Ltd
- NantKwest Inc
- Nkarta Inc
- Novartis AG
- Ono Pharmaceutical Co Ltd
- Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
- Sorrento Therapeutics Inc
- Takara Bio Inc
Highlights of The Chimeric Antigen Receptor Cell Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monotherapy
- Combination Therapy
- By Application:
- Acute Leukemia
- Non-hodgkin's Lymphoma
- Multiple Myeloma
- Transplant Rejection
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chimeric Antigen Receptor Cell Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chimeric antigen receptor cell therapy is a treatment for cancer that uses cells that have been altered to create an immune response against the tumor. These modified cells are then injected into the patient's body. The hope is that this will help destroy the tumor and prevent it from growing further.
Some of the major players in the chimeric antigen receptor cell therapy market are Amgen Inc, Autolus Therapeutics Plc, Beijing Immunochina Medical Science & Technology Co Ltd, Bellicum Pharmaceuticals Inc, Bristol-Myers Squibb Co, bluebird bio Inc, CARsgen Therapeutics Ltd, Celgene Corp, Cell Medica Ltd, Cellular Biomedicine Group Inc, Celularity Inc, Celyad SA, Daiichi Sankyo Co Ltd, Fosun Pharmaceutical AG, Gilead Sciences Inc, Guangzhou Anjie Biomedical Technology Co Ltd, Hangzhou Converd Co Ltd, Hebei Senlang Biotechnology Inc Ltd, HRAIN Biotechnology Co Ltd, Juno Therapeutics Inc, Kite Pharma Inc, Nanjing Legend Biotech Co Ltd, NantKwest Inc, Nkarta Inc, Novartis AG, Ono Pharmaceutical Co Ltd, Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, Sorrento Therapeutics Inc, Takara Bio Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chimeric Antigen Receptor Cell Therapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chimeric Antigen Receptor Cell Therapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chimeric Antigen Receptor Cell Therapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chimeric Antigen Receptor Cell Therapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chimeric Antigen Receptor Cell Therapy Market Size & Forecast, 2018-2028
4.5.1 Chimeric Antigen Receptor Cell Therapy Market Size and Y-o-Y Growth
4.5.2 Chimeric Antigen Receptor Cell Therapy Market Absolute $ Opportunity
Chapter 5 Global Chimeric Antigen Receptor Cell Therapy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Type
5.2.1 Monotherapy
5.2.2 Combination Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chimeric Antigen Receptor Cell Therapy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Applications
6.2.1 Acute Leukemia
6.2.2 Non-hodgkin's Lymphoma
6.2.3 Multiple Myeloma
6.2.4 Transplant Rejection
6.2.5 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chimeric Antigen Receptor Cell Therapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chimeric Antigen Receptor Cell Therapy Analysis and Forecast
9.1 Introduction
9.2 North America Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Type
9.6.1 Monotherapy
9.6.2 Combination Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Applications
9.10.1 Acute Leukemia
9.10.2 Non-hodgkin's Lymphoma
9.10.3 Multiple Myeloma
9.10.4 Transplant Rejection
9.10.5 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chimeric Antigen Receptor Cell Therapy Analysis and Forecast
10.1 Introduction
10.2 Europe Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Type
10.6.1 Monotherapy
10.6.2 Combination Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Applications
10.10.1 Acute Leukemia
10.10.2 Non-hodgkin's Lymphoma
10.10.3 Multiple Myeloma
10.10.4 Transplant Rejection
10.10.5 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chimeric Antigen Receptor Cell Therapy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Type
11.6.1 Monotherapy
11.6.2 Combination Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Applications
11.10.1 Acute Leukemia
11.10.2 Non-hodgkin's Lymphoma
11.10.3 Multiple Myeloma
11.10.4 Transplant Rejection
11.10.5 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chimeric Antigen Receptor Cell Therapy Analysis and Forecast
12.1 Introduction
12.2 Latin America Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Type
12.6.1 Monotherapy
12.6.2 Combination Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Applications
12.10.1 Acute Leukemia
12.10.2 Non-hodgkin's Lymphoma
12.10.3 Multiple Myeloma
12.10.4 Transplant Rejection
12.10.5 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chimeric Antigen Receptor Cell Therapy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Type
13.6.1 Monotherapy
13.6.2 Combination Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chimeric Antigen Receptor Cell Therapy Market Size Forecast by Applications
13.10.1 Acute Leukemia
13.10.2 Non-hodgkin's Lymphoma
13.10.3 Multiple Myeloma
13.10.4 Transplant Rejection
13.10.5 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chimeric Antigen Receptor Cell Therapy Market: Competitive Dashboard
14.2 Global Chimeric Antigen Receptor Cell Therapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen Inc
14.3.2 Autolus Therapeutics Plc
14.3.3 Beijing Immunochina Medical Science & Technology Co Ltd
14.3.4 Bellicum Pharmaceuticals Inc
14.3.5 Bristol-Myers Squibb Co
14.3.6 bluebird bio Inc
14.3.7 CARsgen Therapeutics Ltd
14.3.8 Celgene Corp
14.3.9 Cell Medica Ltd
14.3.10 Cellular Biomedicine Group Inc
14.3.11 Celularity Inc
14.3.12 Celyad SA
14.3.13 Daiichi Sankyo Co Ltd
14.3.14 Fosun Pharmaceutical AG
14.3.15 Gilead Sciences Inc
14.3.16 Guangzhou Anjie Biomedical Technology Co Ltd
14.3.17 Hangzhou Converd Co Ltd
14.3.18 Hebei Senlang Biotechnology Inc Ltd
14.3.19 HRAIN Biotechnology Co Ltd
14.3.20 Juno Therapeutics Inc
14.3.21 Kite Pharma Inc
14.3.22 Nanjing Legend Biotech Co Ltd
14.3.23 NantKwest Inc
14.3.24 Nkarta Inc
14.3.25 Novartis AG
14.3.26 Ono Pharmaceutical Co Ltd
14.3.27 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
14.3.28 Sorrento Therapeutics Inc
14.3.29 Takara Bio Inc
